← Companies|Sonnet Bio
So

Sonnet Bio

S San Francisco CAFounded 202140 employees
Private CapbiotechPrivateOncology
Platform: Cytokine Eng
Market Cap
N/A
All Drugs
2
Clinical Trials
5
Failed / Terminated
0
FDA Approved
1
Drug Pipeline (2 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
KematinibSON-7293Approved4Fusion ProteinKIF18APLK4iCholangiocarcinoma
SON-6232SON-6232Phase 2/31RadioligandSHP2KIF18AiAMLUC
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (6)
2025-06-20
Kematinib Ph3 Readout
Cholangiocarcinoma
Past
2025-09-22
SON-6232 Ph3 Readout
AML
Past
2025-12-21
Kematinib Enrollment Complete
Cholangiocarcinoma
Past
2027-11-08
Kematinib Ph3 Readout
Cholangiocarcinoma
Ph3 Readout
2028-10-23
Kematinib Ph3 Readout
Cholangiocarcinoma
Ph3 Readout
2031-01-11
Kematinib Ph3 Readout
Cholangiocarcinoma
Ph3 Readout